Articles published by Femasys Inc.
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
August 08, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
May 16, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
May 09, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
March 28, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
March 13, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
March 06, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
February 28, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
February 06, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
November 30, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
November 28, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
November 14, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. EU MDR Final Audit Successfully Completed
October 26, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
October 11, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
October 04, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
October 03, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
September 27, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
September 25, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
September 20, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.